Mostrar el registro sencillo del ítem

Artículo

dc.creatorEspada, Caroline R.es
dc.creatorAlbuquerque Wendt, Andreiaes
dc.creatorHornillos, Valentínes
dc.creatorGluenz, Evaes
dc.creatorCoelho, Adriano C.es
dc.creatorUliana, Silvia R. B.es
dc.date.accessioned2022-04-20T10:39:09Z
dc.date.available2022-04-20T10:39:09Z
dc.date.issued2021
dc.identifier.citationEspada, C.R., Albuquerque Wendt, A., Hornillos, V., Gluenz, E., Coelho, A.C. y Uliana, S.R.B. (2021). Ros3 (Lem3p/CDC50) Gene Dosage Is Implicated in Miltefosine Susceptibility in Leishmania (Viannia) braziliensis Clinical Isolates and in Leishmania (Leishmania) major. ACS Infectious Diseases, 7 (4), 849-858.
dc.identifier.issn2373-8227es
dc.identifier.urihttps://hdl.handle.net/11441/132225
dc.description.abstractThe Ros3 protein is a component of the MT-Ros3 transporter complex, considered as the main route of miltefosine entry in Leishmania. L. braziliensis clinical isolates presenting differences in miltefosine susceptibility and uptake were previously shown to differentially express ros3. In this work, we showed that the ros3 gene copy number was increased in the isolate presenting the highest rates of miltefosine uptake and, thus, the highest susceptibility to this drug. The role of the ros3 gene dosage in miltefosine susceptibility was then investigated through a modulation of the gene copy number using two distinct approaches: through an overexpression of ros3 in a tolerant L. braziliensis clinical isolate and in L. major and by generating mono- and diallelic knockouts of this gene in L. major using clustered regularly interspaced short palindromic repeats (CRISPR) Cas9 (Cas = CRISPR-associated). Although the levels of ros3 mRNA were increased at least 40-fold in overexpressing clones, no significant reduction in the half-maximal effective concentration (EC50) for miltefosine was observed in these parasites. The partial or complete deletion of ros3 in L. major, in turn, resulted in a significant increase of 3 and 20 times, respectively, in the EC50 to miltefosine. We unequivocally showed that the ros3 copy number is one of the factors involved in the differential susceptibility and uptake of miltefosine.es
dc.description.sponsorshipWellcome Trust de Reino Unido. 104627/Z/14/Zes
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo. FAPESP 2015/09080-2, 2016/23405-4, 2016/21171-6 y 2018/25299-2es
dc.description.sponsorshipFundação para a Ciência e a Tecnologia de Portugal UID/04413/2020es
dc.description.sponsorshipUK Research and Innovation. MR/P027989/ 1es
dc.description.sponsorshipMinisterio de Educación y Ciencia de España. BQU2003- 04413es
dc.description.sponsorshipMinisterio de Ciencia e Innovación de España. RYC-2017-22294es
dc.formatapplication/pdfes
dc.format.extent10 p.es
dc.language.isoenges
dc.publisherAmerican Chemical Societyes
dc.relation.ispartofACS Infectious Diseases, 7 (4), 849-858.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCRISPR/Cas9es
dc.subjectLeishmania braziliensises
dc.subjectclinical isolateses
dc.subjectdrug resistancees
dc.subjectmiltefosinees
dc.subjecttreatmentes
dc.titleRos3 (Lem3p/CDC50) Gene Dosage Is Implicated in Miltefosine Susceptibility in Leishmania (Viannia) braziliensis Clinical Isolates and in Leishmania (Leishmania) majores
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Química orgánicaes
dc.relation.projectID104627/Z/14/Zes
dc.relation.projectIDFAPESP 2015/09080-2es
dc.relation.projectIDFAPESP 2016/23405-4es
dc.relation.projectIDFAPESP 2016/21171-6es
dc.relation.projectIDFAPESP 2018/25299-2es
dc.relation.projectIDUID/04413/2020es
dc.relation.projectIDBQU2003- 04413es
dc.relation.projectIDRYC-2017-22294es
dc.relation.publisherversionhttps://doi.org/10.1021/acsinfecdis.0c00857es
dc.identifier.doi10.1021/acsinfecdis.0c00857es
dc.journaltitleACS Infectious Diseaseses
dc.publication.volumen7es
dc.publication.issue4es
dc.publication.initialPage849es
dc.publication.endPage858es
dc.contributor.funderWellcome Trust. U.Kes
dc.contributor.funderFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)es
dc.contributor.funderFundação para a Ciência e a Tecnologia. Portugales
dc.contributor.funderMinisterio de Educación y Ciencia (MEC). Españaes
dc.contributor.funderMinisterio de Ciencia e Innovación (MICIN). Españaes

FicherosTamañoFormatoVerDescripción
acsinfecdis.0c00857.pdf1.677MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional